Maravai LifeSciences Holdings, Inc. - Class A common stock (MRVI)

Maravai LifeSciences (NASDAQ:MRVI) reported first-quarter fiscal 2026 results that management said marked a “strong start to 2026,” driven by growth at its TriLink segment, steady contribution from Cygnus, and the impact of restructuring actions taken last year. On the company’s earnings call, CEO

This medical device firm supplies hospitals worldwide with single-use products for critical care, surgery, and interventional procedures.

This energy sector distributor delivers maintenance, repair, and supply chain solutions to industrial clients across a global network.

Arcutis Biotherapeutics develops topical therapies for chronic skin conditions, with a portfolio targeting psoriasis and atopic dermatitis.

Maravai LifeSciences (MRVI) stock fell after Q3 2025 revenue missed estimates. The company reported a net loss and provided full-year guidance below analyst expectations.

Today, August 11, 2025, marks a significant day for investors looking beyond the typical S&P 500 giants, as a diverse array of companies across various sectors unveiled their latest quarterly earnings. These reports, ranging from cybersecurity and fintech to mining and life sciences, offer a crucial granular view into

MRVI earnings call for the period ending December 31, 2024.